Product

DSPE-DOTA-Gd Liposomal

Aliases

ADx-001, DSPE-DOTA-Gd Liposomal Injection

1 clinical trial

1 indication

Indication

Alzheimer's disease

Clinical trial

A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients With Brain Amyloid Deposits as Demonstrated by Amyloid PET

Status: Recruiting, Estimated PCD: 2025-01-01